Assessment of clinical guidelines for medication-related osteonecrosis of the jaw: current status and future directions

Barrette, Louis‐Xavier; Suresh, Neeraj; Salmon, Mandy K.; Ravin, Emma De; Harris, Jacob; Kamdar, Rushabh; Moreira, Alvaro; Rajasekaran, Karthik

doi:10.1016/j.oooo.2022.06.014

Cited by 4 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TRAP staining and activity showed a significant reduction in osteoclast differentiation caused by the mmu_circ_0001066 inhibitor. These results highlight that overexpression of mmu_circ_0001066 prevented BP from suppressing the osteoclast growth of RAW264.7 cells [87][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102] (Figure 3).…”

Section: Discussionmentioning

confidence: 93%

Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw

Caserta,

Stagno,

Gangemi

et al. 2024

IJMS

View full text Add to dashboard Cite

Osteonecrosis of the jaw is the progressive loss and destruction of bone affecting the maxilla or mandible in patients treated with antiresorptive and antiangiogenic agents without receiving prior radiation therapy. The pathogenesis involves the inflammatory pathway of receptor activator of nuclear factor NF-kB ligand and the macrophage colony-stimulating factor, essential for osteoclast precursors survival and proliferation and acting through its receptor c-Fms. Evidence has shown the role of non-coding RNAs in the pathogenesis of osteonecrosis of the jaw and this finding might be useful in diagnosis since these small RNAs could be considered as biomarkers of apoptotic activity in bone. Interestingly, it has been proved that miR-29 and miR-31-5p, acting on specific targets such as CALCR and RhoA, promote programmed-cell death and consequently the necrosis of bone tissue. Specific long non-coding RNAs, instead, have been detected both at reduced levels in patients with multiple myeloma and osteonecrosis, and associated with suppression of osteoblast differentiation, with consequences in the progression of mandible lesions. Among non-coding genic material, circular RNAs have the capability to modify the expression of specific mRNAs responsible for the inhibition of bisphosphonates activity on osteoclastogenesis.

show abstract

Section: Discussionmentioning

confidence: 93%

Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw

Caserta,

Stagno,

Gangemi

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…We acknowledge several potential limitations of this study. It is important to emphasize that a high‐quality designation does not necessarily correspond to the strength of evidence contained within each guideline 11,12,16,30,31 . Even the top‐scoring ASA guideline do not comment on the strength evidence supporting each recommendation.…”

Section: Discussionmentioning

confidence: 99%

“…It is important to emphasize that a high-quality designation does not necessarily correspond to the strength of evidence contained within each guideline. 11,12,16,30,31 Even the top-scoring ASA guideline do not comment on the strength evidence supporting each recommendation. Likewise, it would ultimately be an assumption that high methodological quality leads to the most clinically appropriate guideline.…”

Section: Limitationsmentioning

confidence: 99%

Management of the Difficult Airway: An Appraisal of Clinical Practice Guidelines

Fritz

Monos

et al. 2023

Otolaryngol.--head neck surg.

Self Cite

View full text Add to dashboard Cite

ObjectiveManagement of the difficult airway can be a challenging process, which necessitates actionable recommendations from well‐established guidelines. Herein, clinical practice guideline (CPG) quality is evaluated using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument.Study DesignA systematic literature search was performed using Scopus, EMBASE, and MEDLINE via PubMed.SettingLiterature database.MethodsData were abstracted from relevant guidelines and appraised by 4 expert reviewers in the 6 domains of quality defined by AGREE II. Intraclass correlation coefficients (ICC) were calculated across domains to quantify interrater reliability.ResultsTwelve guidelines met the inclusion criteria. With a mean quality score of 83.1%, the highest quality guideline was authored by the American Society of Anesthesiologists (ASA). Low‐quality content was observed in CPGs authored by the Japanese Society of Anesthesiologists (JSA) and the Chinese Collaboration Group for Emergency Airway Management (CCGEAM). Overall, deficits were most pronounced in domains describing the involvement of stakeholders, developmental rigor, and editorial independence. These findings were consistent among the panel of independent reviewers, with high ICC inter‐rater reliability scores of 58.0% to 70.0% for the referenced domains.ConclusionBy providing a comprehensive appraisal of guidelines, this report may serve as a reference for clinicians seeking to understand and improve upon the developmental quality of difficult airway management resources. According to AGREE II criteria for the quality of the guideline creation process, the 2022 ASA guideline outperforms its predecessors.

show abstract

“…Different biopsy techniques are used depending on the location and type of disease, the patient’s ability to undergo surgery or invasive treatment, and the availability of medical resources ( 70 ).…”

Section: Diagnosismentioning

confidence: 99%

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies

et al. 2023

View full text Add to dashboard Cite

The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of the pleural cavities (inner lining- visceral pleura and outer lining- parietal pleura), peritoneum, pericardium, and tunica vaginalis and is highly resistant to standard treatments. In mesothelioma, the predominant pattern of lesions is a loss of genes that limit tumour growth. Despite the worldwide ban on the manufacture and supply of asbestos, the prevalence of mesothelioma continues to increase. Mesothelioma presents and behaves in a variety of ways, making diagnosis challenging. Most treatments available today for MM are ineffective, and the median life expectancy is between 10 and 12 months. However, in recent years, considerable progress has already been made in understanding the genetics and molecular pathophysiology of mesothelioma by addressing hippo signaling pathway. The development and progression of MM are related to many important genetic alterations. This is related to NF2 and/or LATS2 mutations that activate the transcriptional coactivator YAP. The X-rays, CT scans, MRIs, and PET scans are used to diagnose the MM. The MM are treated with surgery, chemotherapy, first-line combination chemotherapy, second-line treatment, radiation therapy, adoptive T-cell treatment, targeted therapy, and cancer vaccines. Recent clinical trials investigating the function of surgery have led to the development of innovative approaches to the treatment of associated pleural effusions as well as the introduction of targeted medications. An interdisciplinary collaborative approach is needed for the effective care of persons who have mesothelioma because of the rising intricacy of mesothelioma treatment. This article highlights the key findings in the molecular pathogenesis of mesothelioma, diagnosis with special emphasis on the management of mesothelioma.

show abstract

Assessment of clinical guidelines for medication-related osteonecrosis of the jaw: current status and future directions

Cited by 4 publications

References 28 publications

Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw

Highlights on the Effects of Non-Coding RNAs in the Osteonecrosis of the Jaw

Management of the Difficult Airway: An Appraisal of Clinical Practice Guidelines

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies

Contact Info

Product

Resources

About